BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the clinical role of hyperthermia was the focus at the annual European Society for Hyperthermic Oncology (ESHO) Meeting, which was held in Aarhus, Denmark, May 26-28, 2011. The 27th annual ESHO meeting was held in conjunction with the 20th annual European BSD Users Meeting. The object of the ESHO meeting was to review recent developments that will increase the clinical role of hyperthermia.

The scientific program of ESHO 2011 covered the major clinical, physical, and biological developments within hyperthermia. Presentations at the conference included clinical studies on the use of hyperthermia in combination with radiotherapy and/or chemotherapy to treat the following tumors: rectal cancer, soft tissue sarcoma, esophagus cancer, nasal and paranasal sinus cancer, head and neck tumors, pancreatic cancer, pediatric cancers, recurrent breast cancer, and cervical cancer. There were also a number of presentations on the use of thermotherapy with nanotechnology.

Dr. Udo S. Gaipl, Head of Radiation Immunobiology, University Hospital Erlangen, reviewed the data on the biological mechanisms that occur with hyperthermia. Dr. Gaipl stated that data have shown that hyperthermia directly kills cancer cells, stops the proliferation of cancer cells, as well as increases the effectiveness of other cancer therapies. Dr. Gaipl also reported that data have shown that hyperthermia can significantly stimulate the immune system, which increases tumor damage.

About ESHO

ESHO was established to promote research in physics, engineering, biological and clinical sciences relating to the use of hyperthermia in cancer therapy. The aim of the society is to increase collaboration between hyperthermia centers in order to design additional prospective studies to better define the role of hyperthermia.

Source:
BSD Medical Corporation